PubMed Health⌕ Search

Biomedical subjects

C Robinson-Benion

Publications and source records attributed to C Robinson-Benion.

6 recordsLinked to original sources
PubMed1996

Growth retardation and tumour inhibition by BRCA1.

Inherited mutations in BRCA1 predispose to breast and ovarian cancer, but the role of BRCA1 in sporadic breast and ovarian cancer has previously been elusive. Here, we show that retroviral transfer of the wild-type BRCA1 gene inhibits growth in vitro of all breast and ovarian cancer cell lines tested, but not colon or lung cancer cells or fibroblasts. Mutant BRCA1 has no effect on growth of breast cancer cells; ovarian cancer cell growth is not affected by BRCA1 mutations in the 5' portion of the gene, but is inhibited by 3' BRCA1 mutations. Development of MCF-7 tumours in nude mice is inhibited when MCF-7 cells are transfected with wild-type, but not mutant, BRCA1. Most importantly, among mice with established MCF-7 tumours, peritoneal treatment with a retroviral vector expressing wild-type BRCA1 significantly inhibits tumour growth and increased survival.

Animals↗
PubMed1994

Gene transplantation: combined antisense inhibition and gene replacement strategies.

Optimal gene replacement protocols would include both inhibition of the endogenous gene and overexpression of the preferred (or mutant) gene. We have developed a novel gene transfer method to test whether antisense-resistant genes (designed by deletion of antisense RNA target sequences) can replace the function of endogenous genes. Immunoprecipitation studies demonstrated that inducible anti-fos RNA (antisense directed against the c-fos gene) reduces endogenous c-fos expression by 90%, but did not affect the transfected antisense-resistant mutant c-fos genes. Cell growth studies demonstrated that full-length and minimally truncated c-fos expression vectors could restore serum-induced DNA synthesis but that C-terminally truncated Fos mutants including FBR v-fos could not. Transcriptional studies demonstrate that the endogenous c-fos protein contributes to AP-1 activity and normally suppresses regulated SRE (serum response element) activity. This "gene transplant" method for inhibition of endogenous genes and replacement with preferred genes has implications for gene therapy of hereditary hematologic disorders and for the correction or "repair" of oncogenes or tumor suppressor genes in leukemias and lymphomas.

Blood Physiological Phenomena↗
PubMed1992

Differential induction of the c-fos promoter through distinct PDGF receptor-mediated signaling pathways.

The multiple isoforms of PDGF induce fibroblastic mitogenesis through two distinct PDGF receptors, alpha and beta. The molecular mechanisms by which these alpha and beta PDGF receptors regulate gene expression are poorly understood. We present data which indicates that differential induction of c-fos gene expression by PDGF isoforms occurs through distinct PDGF alpha and beta receptor-mediated signaling pathways. Comparison of PDGF-AA with PDGF-BB stimulation showed that PDGF-BB induced prolonged expression of the c-fos gene in BALB/c-3T3 cells, but that PDGF-AA induced more potent activation of the serum response element (SRE) in transient transfection assays. PDGF-AA, which binds alpha but not beta PDGF receptors, could only induce the SRE through a protein kinase C (PKC)-dependent pathway, whereas PDGF-BB, which binds both alpha and beta PDGF receptors, could also induce the SRE through a PKC-independent pathway. These results suggest that PDGF alpha receptors activate the PKC-dependent signaling pathway while PDGF beta receptors also activate a PKC-independent pathway. In addition, we found that PDGF-BB could induce another c-fos promoter element within the -90 to +10 region, suggesting that the more potent mitogenic effect and prolonged c-fos gene expression induced by PDGF-BB may result from cooperativity between more than one c-fos promoter elements.

3T3 Cells↗
PubMed1991

Antisense inhibition of c-myc expression reveals common and distinct mechanisms of growth inhibition by TGF beta and TNF alpha.

Downregulation of the c-myc gene in HL-60 cells is associated with growth inhibition and induction of differentiation. Previous studies have reported that the growth inhibitors TGF beta and TNF alpha downregulate c-myc mRNA levels, suggesting the possibility that these agents may exert some of their phenotypic effects via c-myc downregulation. Our study demonstrates that although both growth inhibitors produce a similar decrease in c-myc protein synthesis, TNF alpha produces a greater growth inhibition and differentiation induction in HL-60 cells. Combined addition of anti-myc oligomer with either growth inhibitor produces no additive effect. In fact, 4 microM anti-myc oligomer produces the same growth and differentiation effects as does 10 ng/ml TGF beta 1. We conclude that downregulation of c-myc expression represents a common mechanism of growth inhibition by TGF beta and TNF alpha, but that TNF alpha possesses an additional effect that is independent of c-myc expression.

Cell Differentiation↗
PubMed1991

Antisense mapping of the c-fos promoter: role of the serum response element.

Using an antisense RNA approach to eliminate endogenous expression of the c-fos protein, we have verified by nuclear run-on and transient expression assays that the Fos protein is a negative regulator of its own transcription in vivo. The negative autoregulation of the c-fos promoter by Fos was further confirmed by overexpression of an antisense-resistant c-fos expressing vector. Antisense mapping of the c-fos promoter demonstrated that the serum responsive element (SRE) represents the major site for c-fos suppression only during the first hour, but that additional adjacent DNA sequences are required for suppression at later times. We propose that antisense inhibition of transcriptional repressors provides a useful method for analyzing the significance and mechanism of transcriptional repression in vivo.

3T3 Cells↗